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ARTICLE
Genome-wide association study with 1000 genomes
imputation identiﬁes signals for nine sex hormone-
related phenotypes
Katherine S Ruth1, Purdey J Campbell2, Shelby Chew2, Ee Mun Lim2,3, Narelle Hadlow2,3,
Bronwyn GA Stuckey2,4, Suzanne J Brown2, Bjarke Feenstra5, John Joseph3, Gabriela L Surdulescu6,
Hou Feng Zheng7, J Brent Richards6,7,8, Anna Murray1,10, Tim D Spector6,10, Scott G Wilson2,4,6,10
and John RB Perry*,1,6,9,10
Genetic factors contribute strongly to sex hormone levels, yet knowledge of the regulatory mechanisms remains incomplete.
Genome-wide association studies (GWAS) have identiﬁed only a small number of loci associated with sex hormone levels, with
several reproductive hormones yet to be assessed. The aim of the study was to identify novel genetic variants contributing to the
regulation of sex hormones. We performed GWAS using genotypes imputed from the 1000 Genomes reference panel. The study
used genotype and phenotype data from a UK twin register. We included 2913 individuals (up to 294 males) from the Twins UK
study, excluding individuals receiving hormone treatment. Phenotypes were standardised for age, sex, BMI, stage of menstrual
cycle and menopausal status. We tested 7 879 351 autosomal SNPs for association with levels of dehydroepiandrosterone
sulphate (DHEAS), oestradiol, free androgen index (FAI), follicle-stimulating hormone (FSH), luteinizing hormone (LH), prolactin,
progesterone, sex hormone-binding globulin and testosterone. Eight independent genetic variants reached genome-wide
signiﬁcance (Po5×10−8), with minor allele frequencies of 1.3–23.9%. Novel signals included variants for progesterone
(P=7.68×10−12), oestradiol (P=1.63×10−8) and FAI (P=1.50×10−8). A genetic variant near the FSHB gene was identiﬁed
which inﬂuenced both FSH (P=1.74×10−8) and LH (P=3.94×10−9) levels. A separate locus on chromosome 7 was
associated with both DHEAS (P=1.82×10−14) and progesterone (P=6.09×10−14). This study highlights loci that are relevant
to reproductive function and suggests overlap in the genetic basis of hormone regulation.
European Journal of Human Genetics (2016) 24, 284–290; doi:10.1038/ejhg.2015.102; published online 27 May 2015
INTRODUCTION
Studies have suggested that genetic factors contribute signiﬁcantly to
population variance in sex hormone levels, however, few associated
genetic variants and genes have been identiﬁed to date.1 As well as
playing an important role in reproduction, variations in sex hormone
levels can have wider implications for health and disease. Reproductive
functions include control of the menstrual cycle, spermatogenesis,
steroidogenesis and lactation, and sex hormone levels have been
implicated in breast cancer, cardiovascular disease, osteoporosis, type 2
diabetes and ageing.2–5 Circulating levels of sex hormones are limited
by sex hormone-binding globulin (SHBG), which is a glycoprotein
that binds and transports oestradiol, testosterone and dehydroepian-
drosterone (DHEA) to a lesser extent.6
GWAS have been performed for dehydroepiandrosterone sulphate
(DHEAS), SHBG, follicle-stimulating hormone (FSH), luteinizing hor-
mone (LH), oestradiol and testosterone.2,4,7–10 The largest of these GWAS
was in over 28 000 males and females and identiﬁed 12 loci associated
with differences in SHBG levels, including four loci with sex-speciﬁc
genetic effects and considerable allelic heterogeneity at the SHBG gene
locus.7 A recent study in 3495 Chinese men has identiﬁed a novel locus
associated with oestradiol and FSH levels, and a further novel locus for
oestradiol.10 A GWAS of total testosterone in males identiﬁed three loci,
including two in the SHBG gene, that were also associated with SHBG
levels.9 In an analysis of males and females combined, eight loci associated
with DHEAS were identiﬁed, of which several were associated with
changes in gene expression levels in pathways linked to ageing.4 GWAS
studies of sex hormone-related phenotypes have explained less than 10%
of variance in oestradiol and SHBG, and less than 5% of variance in
testosterone, DHEAS and FSH.4,7,9,10
In this study, we performed a 1000 Genomes imputed GWAS to
identify novel genetic variants in sex hormone-related phenotypes
where either GWAS has not yet been performed or has not been
performed at 1000-Genomes-density variant coverage.
MATERIALS AND METHODS
Study population
The study included up to 2913 individuals of European ancestry from the
Twins UK study with genotype and phenotype data.11 Twins UK is a supported
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access resource with all data access requests overseen by the Twins UK
Resource Executive Committee. All studies have ethical approval from the
Guy’s and St Thomas’ Ethics Committee (for further information, see
http://www.twinsuk.ac.uk/data-access/). The Twins UK cohort is 51% mono-
zygotic and 49% dizygotic.11 Individuals included in the analysis were mostly
females, however, a small number of males (maximum of 294) were also
included (Supplementary Table 1). Individuals who were pregnant or currently
receiving hormone replacement therapy or oral contraceptive treatments were
excluded from the analysis. Twins UK samples have been included in previous
GWAS of DHEAS and SHBG.4,7
Phenotypes
Plasma levels of DHEAS, FSH, LH, oestradiol, progesterone, prolactin, SHBG
and testosterone were measured by commercial ElectroChemiLuminescent
immunoassays on a Modular Analytics E170 analyser (Roche Diagnostics
GmbH, Mannheim, Germany) using the prescribed assay calibrators and
performed according to the manufacturer’s protocol. The speciﬁc assays used
were: DHEA-S (03000087; CalSet 03000095), FSH (11775863; CalSet II
03032680), LH (11732234; CalSet II 03561097), Estradiol II (03000079; CalSet
II 03064921), Progesterone II (12145383; CalSet 12145391), Prolactin II
(03203093; CalSet 03277356), SHBG (03052001: CalSet 03052028) and
Testosterone II (05200067; CalSet II 05202230). Details of the immunoassays
are provided in the Supplementary Information. Free androgen index (FAI) was
calculated as (testosterone/sex hormone-binding globulin) × 100.12 Individual
sex hormone measures were ﬁtted in a regression model against age, sex, BMI,
phase of menstrual cycle (for females, as a categorical variable), menopausal
status, after which the residuals were transformed to approximate a normal
distribution (either through log, square-root or inverse rank normal transfor-
mation) and outliers more than four standard deviations from the mean were
removed. Single nucleotide polymorphism (SNP) beta estimate effect sizes are
quoted as a per-allele standard deviation change in the covariate-adjusted
transformed residuals. The number of individuals included in the analysis of
each hormone was 2899 for DHEAS, 2906 for oestradiol, 2699 for FAI, 2885 for
FSH, 2881 for LH, 2865 for prolactin, 2689 for progesterone, 2913 for SHBG
and 2657 for testosterone (differences in the numbers for FAI and testosterone
are accounted for by removal of outliers prior to inclusion in the GWAS).
Genotypes
Genotyping of the TwinsUK dataset was done with HumanHap300, Human-
Hap610Q, HumanHap1M Duo and HumanHap1.2M Duo 1M arrays. Imputa-
tion was done in two datasets (n= 2040 from the HumanHap300 array;
n= 3614 from the HumanHap610Q, HumanHap1M Duo and 1.2M Duo 1M
arrays) which were then merged with GTOOL. We performed imputation for
Twins UK study subjects based on 1000 Genomes data as described
previously.13 This involved estimating the phase of contiguous variants in the
subjects using the haplotypes calculated from the 1000 Genomes Project
consisting of 1094 individuals and 2188 haplotypes and the program MACH
1.0.16. The variants in the build-37 November 2010 release of 1000 Genomes
(Phase 1-α interim) were imputed into the phased haplotypes using MINI-
MAC. This resulted in 37 426 733 imputed SNPs. We excluded SNPs that were
imputed with an r2impo0.5. This left 10 879 115 SNPs and after ﬁltering for
minor allele frequency (MAF)40.01 the number fell to 7 879 351. We used a
multi-ethnic reference panel that included 381 Europeans (including 98
Tuscans), 181 Americans, 246 Africans and 286 Asians to improve the quality
of imputation, particularly at lower frequency variants.14
Statistical analysis
We performed a linear mixed-model GWAS analysis for each of the hormones
using the program GEMMA,15 which is capable of accounting for relatedness of
the study subjects when applicable, as well as population stratiﬁcation and
cryptic relatedness. Association statistics using the score test were calculated for
7 879 351 autosomal SNPs passing a MAF ﬁlter of 0.01 and an imputation
quality score of 0.5.
The Bonferroni-corrected P-value for the number of SNPs tested across nine
traits was Po7× 10− 10; however, this is likely to be conservative given that
many SNPs are unlikely to be independent and there are Bayesian arguments
for less conservative P-values.13 Hence, we considered independent signiﬁcant
SNPs to be those with Po5× 10− 8 and more than 1Mb away from another
signiﬁcant SNP. The UCSC Genome Browser and Locus Zoom were used to
identify genes in the regions where signiﬁcant SNPs were identiﬁed.16,17 SNAP,
HaploReg v2, Locus Zoom and Ensembl Biomart were used to identify
HapMap proxies for the 1000 Genomes signals, with linkage disequilibrium
evaluated in the 1000 Genomes Phase I CEU population.17–20 We analysed
expression quantitative trait loci data to identify associations between SNPs
associated with variation in hormone levels and expression levels of nearby
genes in the Multiple Tissue Human Expression Resource (MuTHER).21
Functional annotation of SNPs in strong linkage disequilibrium with the
signiﬁcant signals (r240.8) was performed using wANNOVAR, GWAVA and
HaploReg v2.20,22,23
RESULTS
Hormone phenotypes are correlated
There were strong correlations between three groups of phenotypes
included in our study (Table 1): (i) FAI, SHBG and testosterone;
(ii) progesterone, DHEAS and testosterone; and, (iii) FSH and LH.
FAI was positively correlated with testosterone (r= 0.69) and nega-
tively correlated with SHBG (r=− 0.61), as would be expected because
FAI is a calculated index of the amount of androgen not bound by
SHBG. Testosterone and SHBG were not correlated (r= 0.04).
Progesterone was positively correlated with DHEAS (r= 0.60) and,
to a lesser extent, testosterone (r= 0.44). As a result of the correlation
with testosterone, progesterone was also correlated with FAI (r= 0.39).
DHEAS was also positively correlated with testosterone (r= 0.55) and,
as a result, FAI (r= 0.52). There was a strong positive correlation
between FSH and LH (r= 0.63). Though the other correlations were
smaller, oestradiol was positively correlated with testosterone
(r= 0.22) and was negatively correlated with FSH (r=− 0.24).
Three novel association signals
We identiﬁed new signals for progesterone, oestradiol and FAI
(Table 2). The signal for progesterone (rs112295236, P= 7.68×10− 12,
MAF= 0.06) was identiﬁed in an intergenic region of chromosome
11 (Figure 1). We searched for associations of the progesterone
SNP with other traits that might be inﬂuenced by progesterone
levels, but we found no evidence for association with other
phenotypes (P40.05 in published GWAS of age at menopause,
early menopause, age at menarche, BMI, height, type 2 diabetes
and glycaemic traits, endometriosis, and birth weight (maternal
and foetal genotype)) or in a GWAS of pre-term delivery (ﬁve
gestational age/pre-term delivery traits for mother’s and child’s
genotype, unpublished data). The signals for FAI and oestradiol
were located at 16q12.2 (rs117145500, near LOC643714, P=1.50×10− 8,
MAF=0.06) and 12p13.31 (rs117585797, in ANO2, P=1.63×10− 8,
MAF= 0.01), respectively, and demonstrated no association with other
tested complex traits.
Five signals in known regions
We identiﬁed two signals that replicated previous associations,
and a further three that have been reported previously, but for
other phenotypes (Table 2). The signals for SHBG (rs1641549,
near SHBG gene, P= 1.21 × 10 − 15, MAF= 0.24) and DHEAS
(rs148982377, in ZNF789, P= 1.82 × 10 − 14, MAF= 0.04) have
both been reported previously4,7,9 (Supplementary Table 2). The
signiﬁcant associations for FSH (rs11031005; P= 1.74 × 10− 8,
MAF= 0.13) and LH (rs11031002; P= 3.94 × 10 − 9, MAF= 0.12)
are highly correlated SNPs (r2= 0.79), residing in an intergenic
region near the FSHB gene, and are in linkage disequilibrium with
a published variant for menopause age (rs12294104) (r2= 0.37 for
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FSH (rs11031005) and r2= 0.45 for LH (rs11031002)).24 The
strongest association for progesterone (rs34670419; P= 6.09× 10− 14,
MAF= 0.04) was located on chromosome 7 in the 3’ untranslated
region of ZKSCAN5 (Table 2; Supplementary Figure 1), a locus
previously reported as associated with DHEAS levels.
Two pairs of phenotypes have common signals
We identiﬁed overlaps between signals for FSH/LH and progesterone/
DHEAS (association results for signiﬁcant signals in all pheno-
types are in Supplementary Table 3). The signals for FSH and LH
were in linkage disequilibrium (r2= 0.79), and the most signiﬁcant
SNP for FSH also reached genome-wide signiﬁcance for LH; however,
the direction of effects was the opposite of that expected by the
phenotypic correlation (ie, levels of FSH and LH are positively
correlated, though the minor allele decreased FSH and increased LH
(Supplementary Table 3). The strongest signal for progesterone on
chromosome 7 (rs34670419) was in linkage disequilibrium with the
signal for DHEAS (r2= 1), with allelic effects consistent with the
expected phenotypic correlation (Supplementary Table 3).
Overlap between DHEAS and progesterone variants
To investigate the genetic overlap of DHEAS and progesterone further,
we tested whether ﬁve published variants for DHEAS (identiﬁed prior
to conditional analysis) were associated with progesterone levels in our
data.4 One of these variants reached genome-wide signiﬁcance in
our progesterone data (rs11761528, P= 3.34× 10− 8) (Supplementary
Table 4), and was at the same locus as our strongest progesterone
signal (rs34670419, chr7:99130834). The published signal was not the
strongest signal in our analysis though it was 12 kb from and in
moderate linkage disequilibrium with our top chromosome 7 proges-
terone signal (r2= 0.49). However, four of the ﬁve published variants
were consistent in direction of effect (P= 0.19) and two were
nominally signiﬁcant after Bonferroni correction (Supplementary
Table 4). In addition, we investigated whether our two progesterone
signals were signiﬁcant in other published DHEAS meta-analysis data
by looking up our two progesterone signals in data from Zhai et al.4 A
proxy for our progesterone signal on chromosome 7 (r2= 0.58) was
strongly associated with DHEAS (P= 2.34× 10− 34) and our proges-
terone signal on chromosome 11 showed weak evidence of association
(P= 1.53× 10− 4) (Supplementary Table 5).4
FSH and LH signals overlap with a menopause locus
There was evidence of overlap between the signals for FSH and LH
with a variant for menopause age on chromosome 11 (Supplementary
Tables 6–9). There was moderate linkage disequilibrium between the
signals for FSH and LH and a published variant for menopause age
(rs12294104), with r2= 0.37 for FSH (rs11031005) and r2= 0.45 for
LH (rs11031002), P= 3.02× 10− 7 for FSH and P= 6.25× 10− 7 for
LH.24,25 None of the other published menopause or menarche variants
were associated with FSH or LH at Bonferroni-corrected Po0.05.24,26
Identiﬁcation of potentially causal candidate genes
The signal for SHBG (rs1641549) was 38 kb from the protein-coding
gene SHBG. Four other signals were in linkage disequilibrium with
known polymorphisms that have functional consequences: The signals
for DHEAS (rs148982377) and progesterone (rs34670419) were in
linkage disequilibrium with three SNPs (rs45446698, rs11568825 and
rs11568826; r240.4 for all) that are part of a polymorphism in
the promoter of CYP3A7, which is known to be associated with
lower DHEAS levels (Figure 2). All three of these SNPs were genome-
wide signiﬁcant for DHEAS (P= 2.49× 10− 14 for rs45446698;
P= 1.18 × 10 − 9 for rs11568825 and rs11568826) and one
was genome-wide signiﬁcant for progesterone (rs45446698,
P= 7.7× 10− 11), with the other two almost reaching signiﬁcance
(Po5× 10− 7). The top signals for LH and FSH were within 38 kb of,
and in moderate linkage disequilibrium with, a known polymorphism
(rs10835638) in the promoter of FSHB (rs11031005, r2= 0.62;
Figure 2 SNPs within 300 kb of the signiﬁcant signal for DHEAS on
chromosome 7 (rs148982377; chr7.hg19:g.99075038 T4C). SNPs
indicated are the strongest progesterone signal (rs34670419 (chr7.hg19:
g.99130834G4T)) and those in the CYP3A7 promoter polymorphism that
were identiﬁed in this analysis (rs45446698 (chr7.hg19:g.99332948 T4G),
rs11568825 (chr7.hg19:g.99332986 A4C) and rs11568826 (chr7.hg19:
g.99332978A4T)). Note: Not all genes are shown. Linkage disequilibrium
is based on 1000 Genomes Nov 2010 EUR.
Figure 1 SNPs within 1Mb of the signiﬁcant signal for progesterone on
chromosome 11 (rs112295236; chr11.hg19:g.62915346C4G). Note: Not
all genes are shown. Linkage disequilibrium is based on 1000 Genomes Nov
2010 EUR.
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rs11031002, r2=0.74) (Supplementary Figure 2).27 Although the pub-
lished FSHB promoter polymorphism was not the strongest signal in this
region, it was genome-wide signiﬁcant for association with LH in our
data (P=4.84×10− 9), and nearly signiﬁcant for FSH (P=2.31×10−7)
(Supplementary Table 11). Other candidate genes were identiﬁed by a
search of a 300 kb region around each signal and are listed in
Supplementary Table 10. Functional annotation of the signals with
wANNOVAR did not reveal any additional likely causative variants.
DISCUSSION
In this study of nine sex hormone-related phenotypes, we identiﬁed
three new signals and two pairs of phenotypes with
a common signal. Four of the eight signiﬁcant signals reached a
conservative signiﬁcance level of Po7× 10− 10, including the new
signal for progesterone. This is the ﬁrst published GWAS for the
hormones progesterone, prolactin and the hormone measure FAI, and
we identiﬁed genetic associations for all except prolactin. As we are not
aware of any other genotyped cohorts with measurements for
progesterone and FAI, we have been unable to replicate these ﬁndings.
The hormones DHEAS, FSH, LH, SHBG, testosterone and oestradiol
have been included in previously published GWAS, and we have
compared our results with these existing data.2,4,7–10 This study is, to
our knowledge, one of the ﬁrst published GWAS of hormones using
1000 Genomes Phase I imputed data. Three of the signals we identiﬁed
were low frequency (less than 5%) and had large effect sizes (more
than 50% change relative to standard deviation). In addition to
identifying novel signals, we also observed two previously identiﬁed
signals, demonstrating that true signals can be identiﬁed for these traits
even in modest sample sizes.
The progesterone signal (rs112295236) that we identiﬁed on
chromosome 11 was upstream of SLC22A9, which codes for an
organic anion transporter OAT7 found in the liver. OAT7 is involved
with the transport of DHEAS and oestrone-3-sulphate in exchange for
butyrate, and is thought to be important for the release of oestrogen-3-
sulphate into the blood.28 We did not ﬁnd evidence to support this
hypothesis in expression data, however, such data are only currently
available for a limited range of tissues (skin, lymphoblastoid cell lines
and adipose), not including ovary, which is the main site of
progesterone synthesis. However, there was evidence of an association
between this progesterone signal and DHEAS levels in data from a
published GWAS, albeit at sub-genome-wide signiﬁcance levels,4 and
DHEAS and progesterone were both strongly correlated in our study
(r= 0.60). We postulated that the progesterone variant may be
associated with phenotypic outcomes, such as offspring birth weight,
or age at menopause, but we found no associations in data from other
studies. Of course the effect size of our variant was relatively small and
we may be underpowered to detect additional phenotypic associations.
The variant associated with decreased FAI in our analyses
(rs117145500) showed some evidence of association with increased SHBG
and decreased DHEAS, consistent with the role of DHEA in testosterone
synthesis and the effect of SHBG on the amount of free androgens. This
was supported by a negative correlation of FAI with SHBG in our data
(r=−0.61) and positive correlation with DHEAS (r=0.55).
We identiﬁed a locus showing borderline signiﬁcant association
with oestradiol that requires further replication. The genetic variant
associated with oestradiol (rs117585797) is a low frequency variant
(MAF= 0.013) with a large effect size, and is in an intron of the ANO2
gene on chromosome 12. A previous GWAS of oestradiol levels in
postmenopausal women did not identify any genetic variants reaching
genome-wide signiﬁcance in this region, though this may have been
underpowered to detect this signal.2 Two other genes are present
within the same chromosomal region (vWF and CD9), though there is
not strong evidence to support one as a more likely candidate over the
other. VWF (47 kb away) codes for the von Willebrand factor (vWF)
protein which is involved in haemostasis, aiding platelet adhesion and
preventing factor VIII degradation. Oestradiol has been shown to
increase vWF production by endothelial cells in vitro,29 and in post-
menopausal women, oral oestrogen treatment has been shown to
increase vWF (though transdermal treatment did not show this
effect).30 CD9 (298 kb away) is a widely expressed cell surface
molecule that has been shown to be required for sperm–egg fusion in
mice.31
We provide evidence for overlap in the genetic regulation of two
pairs of hormones whose levels are strongly correlated: FSH and LH
(r= 0.63); and progesterone and DHEAS (r= 0.6). The FSH/LH
variants were in linkage disequilibrium with a functional polymorphism
(-211 G→T) in a progesterone response element of the promoter of
the FSHB gene, which codes for the beta polypeptide of FSH. In
females, FSH receptors are reported in endometrium32 and in
granulosa cells. In granulosa cells, stimulation with FSH augments
the expression of LH receptors.33 In vitro studies have demonstrated
that the allele in linkage disequilibrium with the effect alleles in our
study reduces levels of FSHB expression.34,35 Previous studies provide
conﬂicting data regarding the direction of effect of this polymorphism
on FSH and LH levels.27,36,37 In our study, despite a positive overall
correlation between FSH and LH levels, the genetic variants were
negatively associated with FSH and positively associated with LH.
Although this appears counter-intuitive, a similar situation is seen for
other traits, for example, genetic variants that increase fasting glucose
are not always risk factors for type 2 diabetes.38 Thus, the relationship
between FSH and LH is complex and will involve additional genetic
and non-genetic factors. A previous GWAS including FSH and LH did
not ﬁnd this signal, though this study was in Chinese men10 compared
with our study of mainly female Europeans. Our study sheds light on
part of the biological interaction between FSH and LH, but further
variants need to be identiﬁed to understand this more fully.
The second pair of hormones with overlap in genetic regulation was
DHEAS and progesterone. We identiﬁed a signal for progesterone on
chromosome 7 in linkage disequilibrium with a known signal for
DHEAS, plus evidence for association of progesterone levels with six of
eight known DHEAS SNPs and of DHEAS levels with our newly
identiﬁed chromosome 11 progesterone SNP. Both progesterone and
DHEAS are steroid hormones that have a common precursor in their
synthesis pathways (pregnenolone), but neither are directly synthesised
from each other.3 These hormones were positively correlated in our
data (r= 0.60). The top signal for DHEAS in our study was
rs148982377, which tagged a polymorphism in the promoter of
CYP3A7, which was also in linkage disequilibrium with the top
progesterone signal. CYP3A7 has a progesterone response element that
is thought to regulate expression during pregnancy.39–41 In the same
region is the CYP3A4 gene, which codes for a cytochrome P450 enzyme
that metabolises progesterone, DHEAS, oestrone and testosterone.42
The main limitation of our study is the absence of suitable
replication cohorts for the hormone measures progesterone, oestradiol
and FAI. Half of the signals reached a conservative, Bonferonni-
adjusted signiﬁcance level of Po7×10− 10, giving us conﬁdence in the
ﬁndings for progesterone, DHEAS and SHBG. Although the signals for
FAI, FSH, LH and oestradiol reached a less conservative signiﬁcance
threshold, there are strong arguments for the validity of less stringent
P-values in 1000 Genomes imputed GWAS.13 Further large studies are
required to enable validation of our results. Such studies should also
allow detection of new signals because the power of our study was
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limited by sample size and by the relatedness of the study individuals.
Approximately 10% of our cohort consisted of males, and thus we will
have been more likely to detect genetic effects in females than males,
though our ability to detect genetic variants affecting both sexes should
not have been affected. The cohort used in our study was of European
ancestry and as such our ﬁndings will need to be replicated in other
ethnic populations. Further GWAS studies of these hormones may
beneﬁt from an increase in power by implementing newly emerging
multi-variate methods which would take account of correlations
between the hormones.43 Any additional studies should also consider
the need to directly quantify the effect of the variants, as it is difﬁcult
to relate the adjusted and transformed hormone measure that we used
for our analysis to actual physiological changes. Further studies are
required to address these issues.
In this GWAS of nine sex hormone-related phenotypes, we were
able to detect three new signals (oestradiol, FAI and progesterone
traits), two pairs of signals overlapping with other traits (FSH/LH and
progesterone/DHEAS) and two signals seen before (DHEAS and
SHBG traits). We have demonstrated potential overlap in the genetics
of hormone regulation, as might be expected from common pathways
in hormone synthesis. As well as the overlap in the top signals for
DHEAS and progesterone, and FSH and LH, there were other variants
associated with more than one hormone at lower signiﬁcance levels,
suggesting further commonality in hormone regulation. We identiﬁed
novel genetic variants and potential overlap in the genetic basis of
hormone regulation that will inform future studies, not only of
hormones but also of common diseases, ageing and reproductive
lifespan that include sex related hormones on the aetiological pathway.
CONFLICT OF INTEREST
The authors declare no conﬂict of interest.
ACKNOWLEDGEMENTS
We thank Roche Diagnostics Australia Pty Limited, Castle Hill, Australia, who
provided support for the analysis of the hormones. We thank the volunteer
twins for their participation in the study. Twins UK received funding support
from NIHR Biomedical Research Centre (grant to Guys’ and St Thomas’
Hospitals and King’s College London); the Chronic Disease Research
Foundation; Canadian Institutes of Health Research, the Canadian Foundation
for Innovation, the Fonds de la Recherche en Santé Québec, The Lady Davis
Institute, the Jewish General Hospital and Ministère du Développement
économique, de l'Innovation et de l'Exportation du Quebec. The Australian
National Health and Medical Research Council (NHMRC project grants
1010494, 1048216), and Sir Charles Gairdner Hospital Research (grant
PP2009/028). This work was supported by funding from the Wellcome Trust
(092447/Z/10/Z) and Medical Research Council (MC_U106179472).
1 Vandenput L, Ohlsson C: Genome-wide association studies on serum sex steroid levels.
Mol Cell Endocrinol 2013; 382: 758–766.
2 Prescott J, Thompson DJ, Kraft P et al: Genome-wide association study of circulating
estradiol, testosterone, and sex hormone-binding globulin in postmenopausal women.
PLoS One 2012; 7: e37815.
3 Nussey S, Whitehead S: Endocrinology: An Integrated Approach. Oxford: BIOS
Scientiﬁc Publishers, 2001.
4 Zhai G, Teumer A, Stolk L et al: Eight common genetic variants associated with serum
DHEAS levels suggest a key role in ageing mechanisms. PLoS Genet 2011; 7: e1002025.
5 Perry JRB, Weedon MN, Langenberg C et al: Genetic evidence that raised sex hormone
binding globulin (SHBG) levels reduce the risk of type 2 diabetes. Hum Mol Genet
2010; 19: 535–544.
6 Hammond GL, Bocchinfuso WP: Sex hormone-binding globulin: gene organization and
structure/function analyses. Horm Res 1996; 45: 197–201.
7 Coviello AD, Haring R, Wellons M et al: A genome-wide association meta-analysis of
circulating sex hormone-binding globulin reveals multiple Loci implicated in sex steroid
hormone regulation. PLoS Genet 2012; 8: e1002805.
8 Jin G, Sun J, Kim ST et al: Genome-wide association study identiﬁes a new locus
JMJD1C at 10q21 that may inﬂuence serum androgen levels in men. Hum Mol Genet
2012; 21: 5222–5228.
9 Ohlsson C, Wallaschofski H, Lunetta KL et al: Genetic determinants of serum
testosterone concentrations in men. PLoS Genet 2011; 7: e1002313.
10 Chen Z, Tao S, Gao Y et al: Genome-wide association study of sex hormones, gonadotropins
and sex hormone-binding protein in Chinese men. J Med Genet 2013; 50: 794–801.
11 Moayyeri A, Hammond CJ, Hart DJ, Spector TD: The UK Adult Twin Registry (TwinsUK
Resource). Twin Res Hum Genet 2013; 16: 144–149.
12 Christ-Crain M, Meier C, Huber P, Zimmerli L, Trummler M, Muller B: Comparison of
different methods for the measurement of serum testosterone in the aging male. Swiss
Med Wkly 2004; 134: 193–197.
13 Wood AR, Perry JRB, Tanaka T et al: Imputation of variants from the 1000 Genomes
Project modestly improves known associations and can identify low-frequency variant -
phenotype associations undetected by HapMap based imputation. PLoS One 2013;
8: e64343.
14 Marchini J, Howie B: Genotype imputation for genome-wide association studies.
Nat Rev Genet 2010; 11: 499–511.
15 Zhou X, Stephens M: Genome-wide efﬁcient mixed-model analysis for association
studies. Nat Genet 2012; 44: 821–824.
16 Meyer LR, Zweig AS, Hinrichs AS et al: The UCSC Genome Browser database:
extensions and updates 2013. Nucleic Acids Res 2013; 41: D64–D69.
17 Pruim RJ, Welch RP, Sanna S et al: LocusZoom: regional visualization of genome-wide
association scan results. Bioinformatics 2010; 26: 2336–2337.
18 Flicek P, Amode MR, Barrell D et al: Ensembl 2012. Nucleic Acids Research 2012;
40: D84–D90.
19 Johnson AD, Handsaker RE, Pulit SL, Nizzari MM, O'Donnell CJ, de Bakker PIW: SNAP:
a web-based tool for identiﬁcation and annotation of proxy SNPs using HapMap.
Bioinformatics 2008; 24: 2938–2939.
20 Ward LD, Kellis M: HaploReg: a resource for exploring chromatin states, conservation,
and regulatory motif alterations within sets of genetically linked variants. Nucleic Acids
Res 2012; 40: D930–D934.
21 Grundberg E, Small KS, Hedman AK et al: Mapping cis- and trans-regulatory effects
across multiple tissues in twins. Nat Genet 2012; 44: 1084–1089.
22 Chang X, Wang K: wANNOVAR: annotating genetic variants for personal genomes via
the web. J Med Genet 2012; 49: 433–436.
23 Ritchie GR, Dunham I, Zeggini E, Flicek P: Functional annotation of noncoding
sequence variants. Nat Methods 2014; 11: 294–296.
24 Stolk L, Perry JR, Chasman DI et al: Meta-analyses identify 13 loci associated with age
at menopause and highlight DNA repair and immune pathways. Nat Genet 2012;
44: 260–268.
25 Stolk L, Zhai G, van Meurs JBJ et al: Loci at chromosomes 13, 19 and 20 inﬂuence age
at natural menopause. Nat Genet 2009; 41: 645–647.
26 Elks CE, Perry JR, Sulem P et al: Thirty new loci for age at menarche identiﬁed by a
meta-analysis of genome-wide association studies. Nat Genet 2010; 42: 1077–1085.
27 Schuring AN, Busch AS, Bogdanova N, Gromoll J, Tuttelmann F: Effects of the FSH-
beta-subunit promoter polymorphism -211G-4T on the hypothalamic-pituitary-ovarian
axis in normally cycling women indicate a gender-speciﬁc regulation of gonadotropin
secretion. J Clin Endocrinol Metab 2013; 98: E82–E86.
28 Koepsell H: The SLC22 family with transporters of organic cations, anions and
zwitterions. Mol Aspects Med 2013; 34: 413–435.
29 Harrison RL, McKee PA: Estrogen stimulates von Willebrand factor production by
cultured endothelial cells. Blood 1984; 63: 657–664.
30 Rabbani LE, Seminario NA, Sciacca RR, Chen HJ, Giardina EG: Oral conjugated equine
estrogen increases plasma von Willebrand factor in postmenopausal women. J Am Coll
Cardiol 2002; 40: 1991–1999.
31 Le Naour F, Rubinstein E, Jasmin C, Prenant M, Boucheix C: Severely reduced female
fertility in CD9-deﬁcient mice. Science 2000; 287: 319–321.
32 La Marca A, Carducci Artenisio A, Stabile G, Rivasi F, Volpe A: Evidence for cycle-
dependent expression of follicle-stimulating hormone receptor in human endometrium.
Gynecol Endocrinol 2005; 21: 303–306.
33 Hunzicker-Dunn M, Maizels ET: FSH signaling pathways in immature granulosa cells
that regulate target gene expression: branching out from protein kinase A. Cell Signal
2006; 18: 1351–1359.
34 Benson CA, Kurz TL, Thackray VG: A human FSHB promoter SNP associated with low
FSH levels in men impairs LHX3 binding and basal FSHB transcription. Endocrinology
2013; 154: 3016–3021.
35 Hoogendoorn B, Coleman SL, Guy CA et al: Functional analysis of human promoter
polymorphisms. Hum Mol Genet 2003; 12: 2249–2254.
36 Grigorova M, Punab M, Ausmees K, Laan M: FSHB promoter polymorphism within
evolutionary conserved element is associated with serum FSH level in men. Hum
Reprod 2008; 23: 2160–2166.
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